Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma

J Pediatr Hematol Oncol. 2017 Nov;39(8):e486-e488. doi: 10.1097/MPH.0000000000000956.

Abstract

Neuroblastoma is the most common extracranial malignancy of childhood. Patients with high-risk disease receive multimodal treatment including chemotherapy combinations containing alkylating agents and topoisomerase inhibitors with potential for inducing therapy-related malignancy later in life. Most commonly, cytogenetic changes of pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia involve chromosome 5 or 7. Here we report a novel case of therapy-related myelodysplastic syndrome/acute myeloid leukemia 30 months after treatment for high-risk neuroblastoma with biphenotypic cell surface markers and a not yet described translocation t(1;6)(q25;p23).

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Biopsy
  • Bone Marrow / pathology
  • Child, Preschool
  • Chromosome Banding
  • Chromosomes, Human, Pair 1*
  • Chromosomes, Human, Pair 6*
  • Fatal Outcome
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Immunophenotyping
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / etiology*
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / etiology
  • Neoplasms, Second Primary*
  • Neuroblastoma / complications*
  • Neuroblastoma / diagnosis
  • Neuroblastoma / therapy
  • Phenotype*
  • Translocation, Genetic*
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods